4:48 PM
 | 
Sep 05, 2013
 |  BC Extra  |  Company News

Bicycle, ThromboGenics in ophthalmic deal for bicyclic peptides

Bicycle Therapeutics Ltd. (Cambridge, U.K.) granted ThromboGenics N.V. (Euronext:THR) exclusive rights to develop and commercialize bicyclic peptide inhibitors from Bicycle against a target involved in ophthalmic diseases like diabetic macular...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >